Mouse Genome Informatics
cn1
    Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+

involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
endocrine/exocrine glands
• mutants develop hyperplastic alveolar nodules (J:132088)

tumorigenesis
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive
• mutants develop mammary gland preneoplasia
• some preneoplasia are Esr1-negative while others are Esr1-positive

integument
• mutants develop hyperplastic alveolar nodules (J:132088)


Mouse Genome Informatics
cx2
    Tg(MMTVtTA)1Mam/0
Tg(tetO-Esr1)#Paf/0

involves: C57BL/6 * FVB/N * SJL
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
endocrine/exocrine glands
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls (J:78639)

reproductive system
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls (J:78639)
• when 14 week old males are removed from doxycycline administration for 50 days, epididymis weight is decreased compared to controls (J:78639)
• when 14 week old males are removed from doxycycline administration for 50 days, vas deferens weight is decreased compared to controls (J:78639)
• females raised on doxycycline to block expression of Esr1 exhibit a decrease in the number of days in estrus when the doxycycline is removed and Esr1 is expressed, however overall cycle length is no different from controls (J:78639)
• mutants without doxycycline (expressing Esr1) exhibit a 15% reduction in litter size compared to mutants receiving doxycycline


Mouse Genome Informatics
cx3
    Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0

involves: FVB/N
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
endocrine/exocrine glands
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ (J:96383)
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants (J:96383)
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities (J:96383)
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development (J:96383)
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching (J:96383)
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts (J:96383)
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia (J:96383)
• rates of mammary epithelial cell proliferation are increased compared to controls (J:96383)
• 52% of mutants at 4 months of age show lobular hyperplasia (J:96383)
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias (J:96383)

tumorigenesis
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

integument
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ (J:96383)
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants (J:96383)
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities (J:96383)
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development (J:96383)
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching (J:96383)
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts (J:96383)
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia (J:96383)
• rates of mammary epithelial cell proliferation are increased compared to controls (J:96383)
• 52% of mutants at 4 months of age show lobular hyperplasia (J:96383)
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias (J:96383)

Mouse Models of Human Disease
OMIM IDRef(s)
Breast Cancer 114480 J:96383